Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma.
Journal: Cell reports. Medicine
Published: July 03, 2023
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth.
Journal: Nature
Published: September 08, 2022
The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS.
Journal: Science (New York, N.Y.)
Published: October 07, 2021
Suppressing Nucleotide Exchange to Inhibit KRAS-Mutant Tumors.
Journal: Cancer discovery
Published: May 18, 2021
Diverse alterations associated with resistance to KRAS(G12C) inhibition.
Journal: Nature
Published: March 01, 2021
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.
Journal: Cell
Published: June 03, 2020
Quest for Clinically Effective RAF Dimer Inhibitors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 21, 2020
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition.
Journal: Nature
Published: May 07, 2019
A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy.
Journal: Cell
Published: October 05, 2018
Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 27, 2018
Showing 1-10 of 10
Last Updated: 09/26/2026